Artificial intelligence-powered drug & target discovery company Absci announces the opening of its new research lab located on the 43rd floor of Carnegie Hall Tower in New York City, United States.
The launch of the research center is a part of the company’s efforts to expand its drug discovery capabilities. This new development comes after the company announced its collaboration with NVIDIA and its breakthroughs for in silico antibody lead optimization.
As a hub for Absci’s AI research, the AAIR Lab will build on these recent achievements and continue to expand the nature and scope of therapeutic protein design.
According to the company, its AAIR Lab will help expand Absci’s Denovium Engine AI platform and implement its machine learning pipeline for predicting therapeutic protein sequences and cell line designs to optimize medication candidates for desired properties.
Co-founder and CEO of Absci, Sean McClain, said, “Absci’s expansion into one of the geographic hearts of AI research marks an exciting milestone for our team and brings us closer to our vision for de novo drug and cell line design entirely in silico.”
Sean further added that they are excited to tap into the region’s strong talent pool as they use game-changing technology to provide better pharmaceuticals to patients faster, all while collaborating in a gorgeous setting just steps from Central Park.
United States-based drug research company Absci was founded by Seam McClain in 2011. The organization is best known for developing the Integrated Drug Creation Platform, which uses a single efficient procedure to find novel drug targets, uncover ideal biotherapeutic candidates, and establish cell lines to manufacture them.
“I’m thrilled to be building out our New York-based AI group, which will join our existing multinational team of world-class AI experts as we make strides to accelerate drug discovery with the speed and scale of computation,” said Joshua Meier, Lead AI Scientist at Absci.